Hubei Biocause Heilen Pharmaceutical Co (SZSE:301211) Liabilities-to-Assets : 0.05 (As of Mar. 2026)


SZSE:301211 Hubei Biocause Heilen Pharmaceutical Co Ltd SZSE:301211
69 GF Score
Price ¥11.46
GF Value ¥12.28
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Hubei Biocause Heilen Pharmaceutical Co Liabilities-to-Assets?

Hubei Biocause Heilen Pharmaceutical Co SZSE:301211 +1.51% 69 Liabilities-to-Assets is 0.05 as of Mar. 2026. GuruFocus rates SZSE:301211 with a GF Score™ of 69/100 and a GF Value™ of ¥12.28 (Fairly Valued). The stock has 6 warning signs investors should review.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Hubei Biocause Heilen Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2026 was ¥117.6 Mil. Hubei Biocause Heilen Pharmaceutical Co's Total Assets for the quarter that ended in Mar. 2026 was ¥2,400.1 Mil. Therefore, Hubei Biocause Heilen Pharmaceutical Co's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2026 was 0.05.


Hubei Biocause Heilen Pharmaceutical Co  (SZSE:301211) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Hubei Biocause Heilen Pharmaceutical Co Liabilities-to-Assets Related Terms


Hubei Biocause Heilen Pharmaceutical Co Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Hubei Biocause Heilen Pharmaceutical Co's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hubei Biocause Heilen Pharmaceutical Co Liabilities-to-Assets Chart

Hubei Biocause Heilen Pharmaceutical Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only 0.05 0.09 0.08 0.07 0.05

Hubei Biocause Heilen Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.06 0.06 0.05 0.05

SZSE:301211 vs ZTS: Liabilities-to-Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hubei Biocause Heilen Pharmaceutical Co's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hubei Biocause Heilen Pharmaceutical Co Liabilities-to-Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hubei Biocause Heilen Pharmaceutical Co's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Hubei Biocause Heilen Pharmaceutical Co's Liabilities-to-Assets falls into.


SZSE:301211
69GF Score
Hubei Biocause Heilen Pharmaceutical Co Ltd SZSE:301211
Liabilities-to-Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hubei Biocause Heilen Pharmaceutical Co Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Hubei Biocause Heilen Pharmaceutical Co's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:

Liabilities-to-Assets (A: Dec. 2025 )=Total Liabilities/Total Assets
=128.649/2401.877
=0.05

Hubei Biocause Heilen Pharmaceutical Co's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2026 is calculated as

Liabilities-to-Assets (Q: Mar. 2026 )=Total Liabilities/Total Assets
=117.63/2400.119
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 0.05 mean?
Hubei Biocause Heilen Pharmaceutical Co (SZSE:301211) has a Liabilities-to-Assets of 0.05 as of Mar. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Hubei Biocause Heilen Pharmaceutical Co and its competitors.
Is Hubei Biocause Heilen Pharmaceutical Co's Liabilities-to-Assets too high?
Hubei Biocause Heilen Pharmaceutical Co's current Liabilities-to-Assets is 0.05. Overall, Hubei Biocause Heilen Pharmaceutical Co has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hubei Biocause Heilen Pharmaceutical Co's Liabilities-to-Assets compare to ZTS?
Hubei Biocause Heilen Pharmaceutical Co's Liabilities-to-Assets of 0.05 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Drug Manufacturers company?
A good Liabilities-to-Assets depends on the Drug Manufacturers industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Hubei Biocause Heilen Pharmaceutical Co and its competitors. Hubei Biocause Heilen Pharmaceutical Co's current Liabilities-to-Assets is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hubei Biocause Heilen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hubei Biocause Heilen Pharmaceutical Co (SZSE:301211) is currently considered Fairly Valued. The stock's GF Value™ is ¥12.28, compared to a current price of ¥11.46 — trading 6.7% below its estimated fair value. The current Liabilities-to-Assets is 0.05. Hubei Biocause Heilen Pharmaceutical Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Hubei Biocause Heilen Pharmaceutical Co (SZSE:301211), the current Liabilities-to-Assets is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hubei Biocause Heilen Pharmaceutical Co (SZSE:301211) Overvalued in 2026?

Based on GuruFocus' analysis, Hubei Biocause Heilen Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥11.46 is trading 6.7% below its estimated GF Value™ of ¥12.28. GuruFocus considers Hubei Biocause Heilen Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SZSE:301211:

  • Liabilities-to-Assets: 0.05
  • GF Value™: ¥12.28 vs. price of ¥11.46 (6.7% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the SZSE:301211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hubei Biocause Heilen Pharmaceutical Co Business Description

Address No. 122, Yangwan Road, Dadao District, Jingmen High-tech Zone, Hubei Province, Jingmen, CHN, 448000
Hubei Biocause Heilen Pharmaceutical Co Ltd is engaged in the research and development, production and sales of chemical raw materials and preparation products.
69GF Score

Get the complete analysis for SZSE:301211

Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥11.46
Price
¥12.28
GF Value